Nilesh Kalariya

Association of genetic ancestry with outcomes and toxicity of idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma

Christen Dillard, Hans Lee, Nilesh Kalariya, Naveen G Subramanian et autres

Novel T-cell directed therapies, including chimeric antigen receptor (CAR)-T cells and bispecific antibodies, have transformed treatment for relapsed/refractory multiple myeloma (RRMM). Although myeloma remains largely incurable, BCMA-directed CAR-T therapy has demonstrated unprecedented efficacy with overall response rates (ORR) of 73–100% and complete …

us (code pays fourni par la source)

Enhancing the Safety of Ciltacabtagene Autoleucel in Relapsed Multiple Myeloma (MM):Identification of Potentially Modifiable Risk-Factors Associated with Delayed Neurotoxicity and Non-Relapse Mortality

Surbhi Sidana, Brett Reid, Danai Dima, Lauren C. Peres et autres

Introduction Ciltacabtagene autoleucel (cilta-cel) has shown high efficacy in relapsed MM, but further efforts are needed to mitigate non-ICANS delayed neurotoxicity (DNT) and non-relapse mortality (NRM). Identifying risk factors for DNT and NRM may aid risk mitigation and clinical decision making. Methods …

Minimal Residual Disease Monitoring By Targeted Tracking Serum M-Protein Using Mass Spectrometry (EasyM) in Patients with Multiple Myeloma Receiving Ciltacabtagene Autoleucel

Oren Pasvolsky, Ruchi Singhal, Mahmoud Gaballa, Nilesh Kalariya et autres

us, ca (code pays fourni par la source)

Early Relapse after Ciltacabtagene Autoleucel in High-Risk Multiple Myeloma: Implications for Risk-Adapted Therapy and Clinical Trial Design

Doris K. Hansen, Lauren C. Peres, Danai Dima, Saurabh Zanwar et autres

Predictors of early relapse following ciltacabtagene autoleucel: Informing risk-adapted therapy in relapsed/refractory multiple myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Saurabh Zanwar et autres

Abstract Introduction Ciltacabtagene autoleucel (cilta-cel) has demonstrated unprecedented response rates and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM), but a proportion of patients experience early relapse. Identifying these patients is essential to guide future therapeutic strategies, such as enhanced bridging therapy …

us, Afrique du Sud (code pays fourni par la source)

BCMA CAR T-cell expansion dynamics and toxicity after idecabtagene vicleucel and ciltacabtagene autoleucel for multiple myeloma

Hector Garcia Pleitez, Oren Pasvolsky, Lei Feng, Mahmoud Gaballa et autres

Abstract Introduction: B-cell maturation antigen (BCMA)-targeted chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory multiple myeloma (RRMM) have shown deep and durable responses. However, real-world data on early CAR T-cell expansion dynamics and its association with treatment-related toxicities remain incomplete. This study …

us (code pays fourni par la source)

Enhancing the safety of ciltacabtagene autoleucel in relapsed multiple myeloma (MM): Identification of potentially modifiable risk-factors associated with delayed neurotoxicity and non-relapse mortality

Surbhi Sidana, Brett M. Reid, Danai Dima, Lauren C. Peres et autres

Abstract Introduction: Ciltacabtagene autoleucel (cilta-cel) has shown high efficacy in relapsed MM, but further efforts are needed to mitigate non-ICANS delayed neurotoxicity (DNT) and non-relapse mortality (NRM). Identifying risk factors associated with DNT and NRM may help with risk mitigation by aiding …

us, Afrique du Sud (code pays fourni par la source)

Association between cilta-cel dose and efficacy and toxicity outcomes for patients with Relapsed/Refractory multiple myeloma (RRMM): A real-world analysis from the US multiple myeloma immunotherapy consortium

Ran Reshef, Alexandria Jensen, Christian Gordillo, Brett M. Reid et autres

Abstract Introduction: Ciltacabtagene autoleucel (cilta-cel) is a highly effective BCMA-redirected CAR T-cell therapy for RRMM. While the pivotal CARTITUDE-1 trial established a target dose of 0.75 x 10^6 CAR+ viable T-cells/kg, the approved cell dose is 0.5-1.0 x 10^6 and the optimal …

us, ch (code pays fourni par la source)

Immune effector cell-associated enterocolitis (IEC-EC) across CAR-T products in myeloma and lymphoma: A real world pharmacovigilance analysis

M R Sandhya Belwadi, Mark P. Hamilton, Yinghong Wang, Sairah Ahmed et autres

Abstract Introduction: IEC-EC has emerged as a unique toxicity of BCMA-targeted CAR-T therapy in multiple myeloma (MM) patients (pts), most commonly with ciltacabtagene autoleucel (cilta-cel) (G. Fortuna et al, Blood Cancer J, 2024). While colitis associated with other cancer therapies such as …

us, Afrique du Sud (code pays fourni par la source)

Identifying candidates for outpatient administration of ciltacabtagene autoleucel (Cilta-cel) in relapsed-refractory multiple myeloma (RRMM)

Danai Dima, Lauren C. Peres, Leyla Shune, Brett M. Reid et autres

Abstract Introduction Cilta-cel is a BCMA-directed CAR T-cell therapy that has shown remarkable efficacy in patients with RRMM. As real-world (RW) experience with cilta-cel continues to expand, and with the recent FDA guidance reducing the recommended proximity to the CAR T center …

us, ch (code pays fourni par la source)

Erratum: Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards et autres

Comparison of Standard-of-Care Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

Doris K. Hansen, Lauren C. Peres, Danai Dima, Alicia Richards et autres

PURPOSE: Idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), two B-cell maturation antigen-directed chimeric antigen receptor (CAR) T-cell therapies have demonstrated remarkable efficacy in relapsed/refractory multiple myeloma (RRMM). We compare safety, efficacy, and survival among patients with RRMM treated with standard-of-care (SOC) ide-cel …

us (code pays fourni par la source)